TW200744566A - Topical formulations containing O-desmethyl venlafaxine (ODV) or its salts - Google Patents

Topical formulations containing O-desmethyl venlafaxine (ODV) or its salts

Info

Publication number
TW200744566A
TW200744566A TW095132870A TW95132870A TW200744566A TW 200744566 A TW200744566 A TW 200744566A TW 095132870 A TW095132870 A TW 095132870A TW 95132870 A TW95132870 A TW 95132870A TW 200744566 A TW200744566 A TW 200744566A
Authority
TW
Taiwan
Prior art keywords
odv
topical formulations
salts
formulations containing
desmethyl venlafaxine
Prior art date
Application number
TW095132870A
Other languages
English (en)
Inventor
Rao Tatapudy
Syed M Shah
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37517243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200744566(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200744566A publication Critical patent/TW200744566A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095132870A 2005-09-07 2006-09-06 Topical formulations containing O-desmethyl venlafaxine (ODV) or its salts TW200744566A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71540005P 2005-09-07 2005-09-07

Publications (1)

Publication Number Publication Date
TW200744566A true TW200744566A (en) 2007-12-16

Family

ID=37517243

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095132870A TW200744566A (en) 2005-09-07 2006-09-06 Topical formulations containing O-desmethyl venlafaxine (ODV) or its salts

Country Status (18)

Country Link
US (1) US20070054964A1 (zh)
EP (1) EP1924251A1 (zh)
JP (1) JP2009507078A (zh)
KR (1) KR20080041695A (zh)
CN (1) CN101300002A (zh)
AR (1) AR055629A1 (zh)
AU (1) AU2006287580A1 (zh)
BR (1) BRPI0615769A2 (zh)
CA (1) CA2620164A1 (zh)
CR (1) CR9751A (zh)
EC (1) ECSP088251A (zh)
GT (1) GT200600397A (zh)
IL (1) IL189598A0 (zh)
NO (1) NO20080950L (zh)
PE (1) PE20070430A1 (zh)
RU (1) RU2008106932A (zh)
TW (1) TW200744566A (zh)
WO (1) WO2007030537A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0812501A2 (pt) * 2007-07-12 2015-06-16 Reddys Lab Ltd Dr O-desmetil venlafaxina
JP2011500605A (ja) * 2007-10-16 2011-01-06 アルファファーム ピーティーワイ リミテッド 制御放出医薬配合物
WO2009069140A1 (en) * 2007-11-28 2009-06-04 Dabur Pharma Limited An improved process for preparation of letrozole and its intermediates
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
WO2009155488A2 (en) * 2008-06-19 2009-12-23 Segrub, Llc Novel oxalate salt and crystal of o-desmethylvenlafaxine
WO2010028130A2 (en) * 2008-09-03 2010-03-11 Concert Pharmaceuticals, Inc. Antidepressant compounds
CA2812227C (en) * 2010-10-01 2015-11-24 Shan Dong Luye Pharmaceutical Co., Ltd. Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same
WO2013063794A1 (en) * 2011-11-04 2013-05-10 Oil Crops Research Institute, Chinese Academy Of Agricultural Sciences A growth regulatory factor gene grf2 derived from brassica napus and the use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US20020192302A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of antidepressant drugs using basic enhancers
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
HUP0303128A3 (en) * 2001-02-12 2008-03-28 Wyeth Corp Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it
BR0311693A (pt) * 2002-06-10 2005-03-22 Wyeth Corp Sal de formato de o-desmetil-venlafaxina
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
AU2004270113A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein

Also Published As

Publication number Publication date
PE20070430A1 (es) 2007-05-18
AU2006287580A1 (en) 2007-03-15
CR9751A (es) 2008-05-22
US20070054964A1 (en) 2007-03-08
BRPI0615769A2 (pt) 2011-05-24
IL189598A0 (en) 2008-08-07
WO2007030537A1 (en) 2007-03-15
CA2620164A1 (en) 2007-03-15
JP2009507078A (ja) 2009-02-19
NO20080950L (no) 2008-05-26
CN101300002A (zh) 2008-11-05
RU2008106932A (ru) 2009-10-20
AR055629A1 (es) 2007-08-29
GT200600397A (es) 2007-08-28
KR20080041695A (ko) 2008-05-13
ECSP088251A (es) 2008-04-28
EP1924251A1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
TW200744566A (en) Topical formulations containing O-desmethyl venlafaxine (ODV) or its salts
TW200744678A (en) Transdermal drug delivery devices containing O-desmethyl venlafaxing (ODV) or its salts
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2007143607A3 (en) Method of treating atrophic vaginitis
BRPI0714558B8 (pt) processo para a preparação de (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol
MX2008002457A (es) Formas cristalinas de 1-cloro-4-(??-d-clucopiranos-1-il).
WO2007046102A3 (en) Methods for the treatment of hyperhidrosis
TW200507830A (en) Bronchodilating β -agonist compositions and methods
HK1117824A1 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
TW200716204A (en) Pharmaceutical composition
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
TW200621690A (en) Novel compounds
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2009061374A3 (en) Deuterated fingolimod
UA92178C2 (ru) Средство для борьбы с паразитическими протозоями
WO2008131469A3 (de) Verfahren zur herstellung von hoch reinem 2,4 '-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
UA87515C2 (ru) Фармацевтическая композиция толтеродина с пролонгированным высвобождением
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
BRPI0607436B8 (pt) base cristalina do composto trans-1-((1r,3s)-6-cloro-3-fenil-indan-1-il)-3,3-dimetil-piperazina, sua composição farmacêutica, seus usos, seu método de preparação, método para fabricação do referido composto, bem como base livre do referido composto
ECSP077263A (zh)
NO20074676L (no) Krystallinske former av (1 RS, 3RS, 6RS)-6-dimetylaminometyl-1-(3-metoksy-fenyl)cykloheksan-1,3-diol hydroklorid
UA94042C2 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса